Prothena Corporation plc rose 10.1% on Monday, November 9, 2026, on 741,100 shares. No headline about PRTA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Prothena Corporation plc (PRTA:NASDAQ) closed at $8.16 on November 13, 2026, down 0.85% on the day. The stock trades 30.8% below its 52-week high of $11.80 and 5.6% above its 52-week low of $7.73. Over the past year, it lost 17.8%. Prothena Corporation plc is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, PRTA closed higher on 115 days (46%). Its best day was November 9, 2026 (+10.10%) and its worst was May 11, 2026 (-9.88%). The stock moved 10% or more in a single session 1 time.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson's disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dun Laoghaire, Ireland.
Find more stocks like PRTA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.